Trastuzumab beyond progression: A cost-utility analysis

Annals of Oncology

Volumn 21, Issue 11, 2010, Pages 2161-2168

  Matter Walstra, K W ^a,b   Dedes, K J ^c   Schwenkglenks, M ^a   Brauchli, P ^b   Szucs, T D ^a   Pestalozzi, B C ^d  

^a UNIVERSITY OF BASEL   (Switzerland)

^b SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^c UNIVERSITÄTSSPITAL ZÜRICH   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Cost effectiveness; Cost utility; HER2 positive; Metastatic breast cancer; Second line chemotherapy; Trastuzumab

Indexed keywords

CAPECITABINE; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG WITHDRAWAL; HEALTH CARE SYSTEM; HEART INFARCTION; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; PERICARDIAL EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SIMULATION; TREATMENT RESPONSE;

EID: 77958491291     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq250     Document Type: Article

References (35)

1. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
2. Dawood S, Broglio K, Buzdar AU et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010; 28(1): 92-98.
3. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009; 27: 5838-5847.
4. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743.
5. Tripathy D, Slamon DJ, Cobleigh M et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004; 22: 1063-1070.
6. Gelmon KA, Mackey J, Verma S et al. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer 2004; 5: 52-58; discussion 59-62.
7. Garcia-Saenz JA, Martin M, Puente J et al. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. Clin Breast Cancer 2005; 6: 325-329.
8. Bartsch R, Wenzel C, Hussian D et al. Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study. BMC Cancer 2006; 6: 63.
9. Bartsch R, Wenzel C, Altorjai G et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 2007; 25: 3853-3858.
10. von Minckwitz G, du Bois A, Schmidt M et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 Study. J Clin Oncol 2009; 27: 1999-2006.
11. Meropol NJ, Schulman KA. Cost of cancer care: issues and implications. J Clin Oncol 2007; 25: 180-186.
12. Norum J, Risberg T, Olsen JA. A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis. Ann Oncol 2005; 16: 909-914.
13. Perez-Ellis C, Goncalves A, Jacquemier J et al. Cost-effectiveness analysis of trastuzumab (Herceptin) in HER2-overexpressed metastatic breast cancer. Am J Clin Oncol 2009; 32(5): 492-498.
14. Poncet B, Bachelot T, Colin C et al. Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: a cost-effectiveness analysis. Am J Clin Oncol 2008; 31: 363-368.
15. Garrison LP, Jr., Lubeck D, Lalla D et al. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer 2007; 110: 489-498.
16. Le QA, Hay JW. Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer. Cancer 2009; 115: 489-498.
17. Earle CC, Chapman RH, Baker CS et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000; 18: 3302-3317.
18. Elkin EB, Weinstein MC, Winer EP et al. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2004; 22: 854-863.
19. Schweizerisches Arztneimittelkompedium. www.documed.ch (18 September 2009, date last accessed).
20. Bundesamt für Gesundheit Analyseliste. http://www.bag.admin.ch/themen/krankenversicherung/00263/00264/04185/index.html?lang=de (18 September 2009, date last accessed).
21. Swiss National Tariff Catalogue. http://onb.tarmedsuisse.ch/(18 September 2009, date last accessed).
22. Ess SM, Luscher TF, Szucs TD. High dose lisinopril in heart failure: economic considerations. Cardiovasc Drugs Ther 2002; 16: 365-371.
23. Dedes KJ, Szucs TD, Imesch P et al. Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial. Ann Oncol 2007; 18: 1493-1499.
24. Dedes KJ, Matter-Walstra KW, Schwenkglenks M et al. Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. Eur J Cancer 2009; 45(8): 1397-1406.
25. Schaller G, Fuchs I, Gonsch T et al. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol 2007; 25: 3246-3250.
26. Pettengell R, Schwenkglenks M, Leonard R et al. Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer 2008; 16: 1299-1309.
27. Berkowitz N, Gupta S, Silberman G. Estimates of the lifetime direct costs of treatment for metastatic breast cancer. Value Health 2000; 3: 23-30.
28. Remak E, Brazil L. Cost of managing women presenting with stage IV breast cancer in the United Kingdom. Br J Cancer 2004; 91: 77-83.
29. Miller AA, Rosner GL, Egorin MJ et al. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763. Clin Cancer Res 2004; 10: 8325-8331.
30. Jahanzeb M. Continuing trastuzumab beyond progression. J Clin Oncol 2009; 27: 1935-1937.
31. Ross JS, Slodkowska EA, Symmans WF et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009; 14: 320-368.
32. Orsi C, Bartolozzi B, Messori A et al. Event-free survival and cost-effectiveness in adult acute lymphoblastic leukaemia in first remission treated with allogeneic transplantation. Bone Marrow Transplant 2007; 40: 643-649.
33. Tengs TO. Cost-effectiveness versus cost-utility analysis of interventions for cancer: does adjusting for health-related quality of life really matter? Value Health 2004; 7: 70-78.
34. Ubel PA, Hirth RA, Chernew ME et al. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003; 163: 1637-1641.
35. Schwenkglenks M, Lippuner K. Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland. Osteoporos Int 2007; 18: 1481-1491.